Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Sebacoyl Dinalbuphine Ester
1. Sebacoyldinalbuphine
2. Dinalbuphine Sebacate
3. Naldebain
4. 311768-81-7
5. 464oxx39y6
6. Bis[(4r,4as,7s,7ar,12bs)-3-(cyclobutylmethyl)-4a,7-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-9-yl] Decanedioate
7. Sebacoyl Dinalbuphine Ester
8. Nalbuphine Sebacate [inn]
9. Unii-464oxx39y6
10. Chembl1823241
11. Dtxsid601336353
12. Dinalbuphine Sebacate [inn]
13. Nalbuphine Sebacate [who-dd]
14. Db15341
15. Q27258899
16. Bis(17-(cyclobutylmethyl)-4,5alpha-epoxy-6alpha,14-dihydroxymorphinan-3-yl) Decanedioate
17. Bis(17-(cyclobutylmethyl)-4,5.alpha.-epoxy-6.alpha.,14-dihydroxymorphinan-3-yl) Decanedioate
18. Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, 3,3'-decanedioate, (5.alpha.,6.alpha.)-(5'.alpha.,6'.alpha.)-
19. Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, 3,3'-decanedioate, (5alpha,6alpha)-(5'alpha,6'alpha)-
Molecular Weight | 881.1 g/mol |
---|---|
Molecular Formula | C52H68N2O10 |
XLogP3 | 5 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 17 |
Exact Mass | 880.48739637 g/mol |
Monoisotopic Mass | 880.48739637 g/mol |
Topological Polar Surface Area | 159 Ų |
Heavy Atom Count | 64 |
Formal Charge | 0 |
Complexity | 1640 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 10 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
LT1001 is the world's first week-long extended-release analgesic injection. The approval from Singapore has significance in accelerating the introduction of LT1001 in Southeast Asia.
Lead Product(s): Nalbuphine Sebacate
Therapeutic Area: Neurology Brand Name: LT1001
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
Lead Product(s) : Nalbuphine Sebacate
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LT1001 is the world's first week-long extended-release analgesic injection. The approval from Singapore has significance in accelerating the introduction of LT1001 in Southeast Asia.
Brand Name : LT1001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2020
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?